Verification of Genes Differentially Expressed in Neuroblastoma Tumours: a Study of Potential Tumour Suppressor Genes

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2009 Aug 19

PMID 19686582

Citations 13

Authors

Kaisa Thorell

Annika Bergman

Helena Caren

Staffan Nilsson

Per Kogner

Tommy Martinsson

Frida Abel

Affiliations

Soon will be listed here.

Abstract

Background: One of the most striking features of the childhood malignancy neuroblastoma (NB) is its clinical heterogeneity. Although there is a great need for better clinical and biological markers to distinguish between tumours with different severity and to improve treatment, no clear-cut prognostic factors have been found. Also, no major NB tumour suppressor genes have been identified.

Methods: In this study we performed expression analysis by quantitative real-time PCR (QPCR) on primary NB tumours divided into two groups, of favourable and unfavourable outcome respectively. Candidate genes were selected on basis of lower expression in unfavourable tumour types compared to favourables in our microarray expression analysis. Selected genes were studied in two steps: (1) using TaqMan Low Density Arrays (TLDA) targeting 89 genes on a set of 12 NB tumour samples, and (2) 12 genes were selected from the TLDA analysis for verification using individual TaqMan assays in a new set of 13 NB tumour samples.

Results: By TLDA analysis, 81 out of 87 genes were found to be significantly differentially expressed between groups, of which 14 have previously been reported as having an altered gene expression in NB. In the second verification round, seven out of 12 transcripts showed significantly lower expression in unfavourable NB tumours, ATBF1, CACNA2D3, CNTNAP2, FUSIP1, GNB1, SLC35E2, and TFAP2B. The gene that showed the highest fold change in the TLDA analysis, POU4F2, was investigated for epigenetic changes (CpG methylation) and mutations in order to explore the cause of the differential expression. Moreover, the fragile site gene CNTNAP2 that showed the largest fold change in verification group 2 was investigated for structural aberrations by copy number analysis. However, the analyses of POU4F2 and CNTNAP2 showed no genetic alterations that could explain a lower expression in unfavourable NB tumours.

Conclusion: Through two steps of verification, seven transcripts were found to significantly discriminate between favourable and unfavourable NB tumours. Four of the transcripts, CACNA2D3, GNB1, SLC35E2, and TFAP2B, have been observed in previous microarray studies, and are in this study independently verified. Our results suggest these transcripts to be markers of malignancy, which could have a potential usefulness in the clinic.

Citing Articles

The regulatory role of AP-2β in monoaminergic neurotransmitter systems: insights on its signalling pathway, linked disorders and theragnostic potential.

Al-Sabri M, Nikpour M, Clemensson L, Attwood M, Williams M, Rask-Anderson M Cell Biosci. 2022; 12(1):151.

PMID: 36076256 PMC: 9461128. DOI: 10.1186/s13578-022-00891-7.

Co-expression of transcription factor AP-2beta (TFAP2B) and GATA3 in human mammary epithelial cells with intense, apicobasal immunoreactivity for CK8/18.

Raap M, Gierendt L, Werlein C, Kuehnle E, Kreipe H, Christgen M J Mol Histol. 2021; 52(6):1257-1264.

PMID: 34117603 PMC: 8616868. DOI: 10.1007/s10735-021-09980-2.

CACNA2D3 Enhances the Chemosensitivity of Esophageal Squamous Cell Carcinoma to Cisplatin via Inducing Ca-Mediated Apoptosis and Suppressing PI3K/Akt Pathways.

Nie C, Qin X, Li X, Tian B, Zhao Y, Jin Y Front Oncol. 2019; 9:185.

PMID: 31001468 PMC: 6454090. DOI: 10.3389/fonc.2019.00185.

Heterozygous Missense Variants: Risk Factors for Autism Spectrum Disorder and/or Other Pathologies?.

Canali G, Goutebroze L J Exp Neurosci. 2018; 12:1179069518809666.

PMID: 30450007 PMC: 6236484. DOI: 10.1177/1179069518809666.

Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

Ikram F, Ackermann S, Kahlert Y, Volland R, Roels F, Engesser A Mol Oncol. 2015; 10(2):344-59.

PMID: 26598443 PMC: 5528952. DOI: 10.1016/j.molonc.2015.10.020.

References

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

Budhram-Mahadeo V, Irshad S, Bowen S, Lee S, Samady L, Tonini G . Proliferation-associated Brn-3b transcription factor can activate cyclin D1 expression in neuroblastoma and breast cancer cells. Oncogene. 2007; 27(1):145-54. DOI: 10.1038/sj.onc.1210621. View

Caren H, Abel F, Kogner P, Martinsson T . High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008; 416(2):153-9. DOI: 10.1042/bj20081834. View

Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, De Pontual L, Combaret V . Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature. 2008; 455(7215):967-70. DOI: 10.1038/nature07398. View

Eggert A, Grotzer M, Zuzak T, Ikegaki N, Zhao H, Brodeur G . Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. Eur J Cancer. 2001; 38(1):92-8. DOI: 10.1016/s0959-8049(01)00347-1. View

Breslow N, McCann B . Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971; 31(12):2098-103. View

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

Warnat P, Oberthuer A, Fischer M, Westermann F, Eils R, Brors B . Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes. BMC Cancer. 2007; 7:89. PMC: 1904223. DOI: 10.1186/1471-2407-7-89. View

Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D . Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res. 2006; 66(12):6050-62. DOI: 10.1158/0008-5472.CAN-05-4618. View

10.

Maris J, Matthay K . Molecular biology of neuroblastoma. J Clin Oncol. 1999; 17(7):2264-79. DOI: 10.1200/JCO.1999.17.7.2264. View

11.

Fischer M, Oberthuer A, Brors B, Kahlert Y, Skowron M, Voth H . Differential expression of neuronal genes defines subtypes of disseminated neuroblastoma with favorable and unfavorable outcome. Clin Cancer Res. 2006; 12(17):5118-28. DOI: 10.1158/1078-0432.CCR-06-0985. View

12.

Ebauer M, Wachtel M, Niggli F, Schafer B . Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene. 2007; 26(51):7267-81. DOI: 10.1038/sj.onc.1210525. View

13.

Evans A, DAngio G, Propert K, Anderson J, Hann H . Prognostic factor in neuroblastoma. Cancer. 1987; 59(11):1853-9. DOI: 10.1002/1097-0142(19870601)59:11<1853::aid-cncr2820591102>3.0.co;2-f. View

14.

Martinsson T, Sjoberg R, Hedborg F, Kogner P . Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. Cancer Res. 1995; 55(23):5681-6. View

15.

Irshad S, Pedley R, Anderson J, Latchman D, Budhram-Mahadeo V . The Brn-3b transcription factor regulates the growth, behavior, and invasiveness of human neuroblastoma cells in vitro and in vivo. J Biol Chem. 2004; 279(20):21617-27. DOI: 10.1074/jbc.M312506200. View

16.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A . Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002; 3(7):RESEARCH0034. PMC: 126239. DOI: 10.1186/gb-2002-3-7-research0034. View

17.

Maris J . The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005; 17(1):7-13. DOI: 10.1097/01.mop.0000150631.60571.89. View

18.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

19.

Mosse Y, Diskin S, Wasserman N, Rinaldi K, Attiyeh E, Cole K . Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer. 2007; 46(10):936-49. DOI: 10.1002/gcc.20477. View

20.

Caren H, Erichsen J, Olsson L, Enerback C, Sjoberg R, Abrahamsson J . High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics. 2008; 9:353. PMC: 2527340. DOI: 10.1186/1471-2164-9-353. View